Kenneth Ndugga-Kabuye, M.D., FACMG
Vice President, Cell & Gene Therapy
Dr. Ken Ndugga-Kabuye is Vice President, Cell & Gene Therapy at Premier Research. He brings direct experience supporting drug development candidates for clinical studies leveraging innovative approaches in the treatment of disease, inclusive of cell and gene therapies, synthetic biotics, RNA therapies, and enzyme replacement therapies.
In previous roles, Dr. Ndugga-Kabuye has supported CRO and biotechnology clients in the ATMP space. Dr. Ndugga-Kabuye is a clinical geneticist with residency and fellowship training in medical genetics and genomics from the University of Washington in Seattle, WA, US. He is board certified by the American Board of Medical Genetics and Genomics in Clinical Genetics and Genomics. He holds a medical license in Washington State and California. He is a Diplomate of the American Board of Medical Genetics and Genomics. He is a member of the American Society of Human Genetics (ASHG), the European Society of Human Genetics (ESHG), the American College of Medical Genetics (ACMG), the African Society of Human Genetics (AfSHG), the American Medical Association (AMA) and the American Academy of Pediatrics (AAP).
Paulla Dennis
Executive Director, Program Strategy, Rare Disease, Pediatrics, Cell & Gene Therapy
Paulla Dennis has been dedicated to rare disease and pediatric clinical research for more than 25 years, specializing in gene therapy for the last 10+ years. She is highly experienced in operational delivery after spending 17 years at a pediatric hospital running the Clinical Research Services group, where she delivered pivotal studies in several rare pediatric disorders inclusive of gene therapies. Paulla has an additional 8 years’ experience in the CRO setting in startup project management as well as in program strategy, delivering rare, pediatric disease and advanced therapies studies.
As Executive Director, Program Strategy, Paulla advises, consults, plans, and directs the design and strategy for prospective and ongoing rare, pediatric, and gene and cell therapy studies. In her current role, she provides strategies and solutions for operational excellence in this complex clinical research setting with a focus on patient and family pathway planning and comprehensive site assessment and educational support.
Paulla has extensive experience in phase 1-4 studies in a global setting, including autosomal, neurological, metabolic, and endocrine diseases. Her key experience areas include rare/ultra-rare disease, pediatrics, gene therapies, and neurological (neuropsychological, neurodegenerative, and neuromuscular) indications.